Update on the mechanism of action of antiepileptic drugs

Epilepsia

Volumn 37, Issue SUPPL. 6, 1996, Pages

  Meldrum, Brian S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anticonvulsants; Felbamate; GABA; Gabapentin; Lamotrigine; Membrane potentials; Neurotransmitters; Remace mide; Tiagabine; Topiramate; Vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; ANTICONVULSIVE AGENT; FELBAMATE; GABAPENTIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; EPILEPSY; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; SODIUM TRANSPORT;

EID: 0029831493     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb06038.x     Document Type: Conference Paper

References (66)

1. Macdonald RL, Meldrum BS. General principles: principles of antiepileptic drug action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th edition. New York: Raven Press, 1995:61-77.
2. Macdonald RL, Kelly KM. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia 1994;35(suppl 4):S41-50.
3. + channels expressed in a mammalian cell line by local anaesthetic, antiarrhythmic and anticonvulsant drugs. Mol Pharmacol 1991;40:756-65.
4. + current of mammalian CNS neurones. Neuroreport 1995;6:1778-80.
5. Huguenard JR, Prince DA. Intrathalamic rhythmicity studied in vitro: nominal T-current modulation causes robust antioscillatory effects. J Neurosci 1994;14:5485-502.
6. Kelly KM, Gross RA, Macdonald RL. Valproic acid selectively reduces the low threshold (T) calcium current in rat nodose neurons. Neurosci Lett 1990;116:233-8.
7. Gross RA, Macdonald RL. Differential actions of pentobarbitone on calcium current components of mouse sensory neurones in culture. J Physiol (Lond) 1988;405:187-203.
8. French-Mullen JMH, Barker JL, Rogawski MA. Calcium current block by (-)-pentobarbital, phenobarbital, and CHEB but not (+)-pentobarbital in acutely isolated hippocampal CA1 neurons: comparison with effects on GABA-activated Cl current. J Neurosci 1993;13:3211-21.
9. Stefani A, Pisani A, De Murtas M, Mercuri NB, Marciani MG, Calabresi P. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage activated calcium currents. Epilepsia 1995;36:997-1002.
10. Turner TJ, Adams ME, Dunlap K. Calcium channels coupled to glutamate release identified by omega-Aga-IVA. Science 1992;258:310-3.
11. 2+ channel types coexist to regulate synaptosomal neurotransmitter release. Proc Natl Acad Sci USA 1993;90:9518-22.
12. Olivera BM, Miljanich GP, Ramachandran J, Adams MF. Calcium channel diversity and neurotransmitter release: the omega conotoxins and omega anatoxins. Annu Rev Biochem 1994;63:823-67.
13. Miljanich GP, Ramachandran J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol 1995;35:707-34.
14. Zona C, Tancredi V, Palma E, Pirrone GC, Avoli M. Potassium currents in rat cortical neurons in culture are enhanced by the antiepileptic drug carbamazepine. Can J Physiol Pharmacol 1990;68:545-7.
15. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal-activated sodium channels. Epilepsy Res 1992;13:107-12.
16. Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 1993;266:820-35.
17. + channels in rat hippocampal neurones. Pflugers Arch 1995;430:437-46.
18. Clark B, Hutchison JB, Jamieson V, Jones T, Palmer GC, Scheyer RD. Potential antiepileptic drugs: remacemide hydrochloride. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th edition. New York: Raven Press, 1995:1035-44.
19. Coulter DA, Sombati S, Delorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993;34:S123.
20. White HS, Wolf HH, Swinyard EA, Skeen GA, Sofia RD. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 1992;33:564-73.
21. Wamil AW, McLean MJ. Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res 1994;17:1-11.
22. Stefani A, Spadoni F, Siniscalchi A, Bernardi G. Lamotrigine inhibits calcium currents in cortical neurons: functional implications. Eur J Pharmacol (in press).
23. Stefani A, Calabresi P, Pisani A, Mercuri NB, Siniscalchi A, Bernardi G. Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther 1996;277:121-127.
24. Walton NY, Jaing Q, Hyum B, Treiman DM. Lamotrigine vs phenytoin for treatment of status epilepticus: comparison in an experimental model. Epilepsy Res 1996;24:19-28.
25. Catterall WA. Cellular and molecular biology of voltage-gated sodium channels. Physiol Rev 1992;72:S15-48.
26. Sieghart W. Structure and pharmacology of GABA A receptor subtypes. Pharmacol Rev 1995;47:181-234.
27. Rabow LE, Russek SJ, Farb DH. From ion currents to ge- nomic analysis: recent advances in GABA A receptor research. Synapse 1995;21:189-274.
28. Granger P, Biton B, Faure C, et al. Modulation of the GABA type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molec Pharmacol 1995;47:1189-96.
29. Abenzodiazepine receptor heterogenicity: neurophysiological implications. Neuropharmacology 1995;34:245-54.
30. A receptor subtypes. J Pharmacol Exp Ther 1993;266:385-91.
31. Turski L, Stephens DN, Jensen LH, et al. Anticonvulsant action of the β-carboline abecarnil-studies in rodents and baboons, Papio papio. J Pharmacol Exp Ther 1990;253:344-52.
32. Lippert B, Metcalf BW, Jung MJ, Casara P. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferase in mammalian brain. Eur J Biochem 1977;74:441-5.
33. Jung MJ, Palfreyman MG. Vigabatrin mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th edition. New York: Raven Press, 1995;903-13.
34. Kälviäinen R, Halonen T, Pitkänen A, Riekkinen PJ. Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine. J Neurochem 1993;60:1244-50.
35. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of gamma-aminobutyric acid, glutamate, and glutamine in human brain. Epilepsia 1995;36:457-64.
36. Waniewski RA, Martin DL. Repeated administration of gama-vinylGABA reduces rat brain glutamine synthetase activity. J Neurochem 1995;65:355-62.
37. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995;36:612-26.
38. Borden LA, Dhar TGM, Smith KE, Weinshank RL, Branchek TA, Gluchowski C, Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol Mol Pharmacol 1994;269:219-24.
39. Minelli A, Brecha NC, Karschin C, DeBiasi S, Conti F. GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex. J Neurosci 1995;15:7734-46.
40. Fink-Jensen A, Suzdak PD, Swedberg MDB, Judge ME, Hansen L, Nielsen PG. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992;220:197-201.
41. Löscher W, Honack D, Taylor CP. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci Lett 1991;128:150-4.
42. Goldlust A, Su T-Z, Welty DF, Taylor CP, Oxender DL. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res 1995;22:1-11.
43. Gotz E, Feuerstein TJ, Lais A, Meyer DK. Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 1993;43:636-8.
44. Honmou O, Kocsis JD, Richerson GB. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res 1995;20:193-202.
45. Honmou O, Oyelese AA, Kocsis JD. The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res 1995;692:273-7.
46. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain GABA in patients with epilepsy. Ann Neurol 1996;39:95-9.
47. Rock DM, Kelly KM, Macdonald RL. Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons. Epilepsy Res 1993;16:89-98.
48. 3H]gabapentin to a novel site in rat brain. Autoradiographic studies. Eur J Pharmacol Mol Pharmacol 1993;244:303.
49. 3H]gabapentin may label a system L like neutral amino acid carrier in brain. Eur J Pharmacol Mol Pharmacol 1993;247:341-5.
50. + + channel. J Biol Chem 1996;271:5768-76.
51. Shank RP, Gardock JP, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
52. Shank RP. Preclinical profile of topiramate, a novel anticonvulsant. Adv AED Ther 1995;1:1-6.
53. Brown SD, Wolf HH, Swinyard EA, Twyman RE, White HS. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 1993;34(suppl 2):122-3.
54. A receptors. Science 1995;269:977-81.
55. A receptor system. Epilepsia 1991;32:389-91.
56. A receptors. Ann Neurol 1994;35:229-34.
57. Macdonald RL, Barker JL. Different actions of anticonvul- sant and anesthetic barbiturates revealed by use of cultured mammalian neurons. Science 1978;200:775-7.
58. Simmonds MA, Horne AL. Antagonism of excitatory amino acids by barbiturates. In: Hicks TP, Lodge D, McLennan H, eds. Excitatory amino acid transmission. New York: Alan R. Liss, 1987:99-105.
59. Taverna FA, Cameron B-R, Hampson DL, Wang L-Y, MacDonald JF. Sensitivity of AMPA receptors to pentobarbital. Eur J Pharmacol Mol Pharmacol 1994;267:R3-5.
60. Chapman AC. Excitatory neurotransmission and antiepileptic drug development: a status report: In: Pedley TA, Meldrum BS, eds. Recent advances in epilepsy. Vol. 6, Edinburgh: Churchill Livingstone, 1995:1-21.
61. Chapman AC, Smith SE, Meldrum BS. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res 1991;9:92-6.
62. Löscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res 1993;18:485-502.
63. McCabe RT, Wasterlain CG, Kucharczyk N, Sofia RD, Vogel JR. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther 1993;264:1248-52.
64. White HS, Harmsworth WL, Sofia RD, Wolf HH. Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 1995;20:41-8.
65. Subramaniam S, Rho JM, Penix L, Donevan SD, Fielding RP, Rogawski MA. Felbamate block of the N-methyl-D-aspartate receptor. J Pharmacol Exp Ther 1995;273:878-86.
66. Pisani A, Stefani A, Siniscalchi A, Mercuri NB, Bernardi G, Calabresi P. Electrophysiological actions of felbamate on rat striatal neurones. Br J Pharmacol 1995;116:2053-61.